FAQs & How to use this site
Home | About Us | Contact Us
The Front Line
The Front Line: Charles D. Blanke, MD, SWOG Chair
ABOUT

PREVIOUS POSTS September 2017

August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013

President Carter's Cancer Treatment Pioneer is Right Here

Aug 21, 2015 - We learned this week that former President Jimmy Carter has cancer. He has multiple brain metastases -- four spots of melanoma, each the size of the head of a pin. President Carter will receive radiation therapy and a drug pioneered by one of our very own -- a drug that's also the subject of a brand-new SWOG study.

The drug is pembrolizumab, or Keytruda, a Merck immunotherapeutic. Dr. Antoni Ribas, SWOG's melanoma chair and a long-time UCLA professor and researcher, has conducted groundbreaking work on this medication. Last year, Dr. Ribas led a global Phase III study that showed, perhaps surprisingly, perhaps not, that pembro led to better outcomes than the standard of care not only for patients with melanoma but also for patients with lung cancer. In April 2014, Dr. Ribas presented these results at the American Association for Cancer Research annual meeting, and published them in the New England Journal of Medicine. Five months later, the U.S. Food and Drug Administration approved pembro for patients with metastatic melanoma.

"It's a great new agent," says Ribas. Along with other new immunotherapy drugs, such as nivolumab, pembro works by blocking PD-1, a protein that brakes our immune response. When you take the drug, Ribas says: "It's like taking those brakes off. It lets the immune system mount a better response against cancer."

Dr. Ribas talks mechanism deftly. That's because, like many SWOG investigators, Ribas not only conducts clinical trials, but bench research. Ribas has studied the immune system for 20 years, and published papers on PD-1 and its effects in Nature and the Lancet. Now, after two years of work, he is eagerly awaiting the imminent launch of S1404, a trial led by Dr. Ken Grossmann. This SWOG trial will compare high dose interferon against pembro in patients at high risk for a recurrence of their melanoma.

The beauty of Dr. Ribas's story lies in its layers.

He embraces basic science, and brings the lessons he learns at the bench into the clinic. He also knows the power of persistence. "You used to have to hide yourself when it came to immunotherapies," he says. "They were very controversial. Now we are seeing people living a new life on this drug."

Dr. Ribas says the big message is this: Have the courage to pursue your research ideas, no matter how outlandish they may seem. One day, your pipe dream may be healing a president.

 

 
     
SWOG Logo Disclaimer | Copyright ©2000-2017 SWOG. All rights reserved.
Design by nuMedia Group Inc. | Hosting by WorldPost Technologies, Inc.
SWOG is FISMA CertifiedSWOG is FISMA Certified